Alpha¹ by KaimenConfidential

Kaimen Rigor review

Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.

Janjigian YY, Oh DY, Pelster M, Wainberg ZA, Prusty S, Nelson S, DuPage A, Thompson A, Koralek DO, Sison EAR, Rha SY

DOI: 10.1038/s41591-025-04022-w
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/aa5225dc-0607-4531-b41f-bd06ad2b8e66 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

CitationsCitations & links (capped) ×10−1★
IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★

Citations & links are capped at −1★ combined, however many are flagged.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoints are ORR, PFS, and OS. While OS is a hard clinical outcome, the primary endpoint is ORR (a surrogate), and the paper does not demonstrate target engagement at the tested dose (no PK/PD data) nor cite validated evidence linking ORR to long-term clinical benefit in this setting. The efficacy claim is based on tumor response and survival metrics without explicit validation of ORR as a surrogate for OS.
“The dual primary endpoints of safety and investigator-assessed ORR were evaluated in patients who enrolled and received any study treatment (treated analysis population).”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported ORR of 59% and median OS of 26.7 months are compared favorably to historical controls, but the effect size is not anchored to a minimal clinically important difference or a predefined threshold for clinical meaningfulness. The study is descriptive without formal hypothesis testing, and the magnitude of benefit is not explicitly justified as clinically material beyond statistical confidence intervals.
“Results from the EDGE-Gastric study arm A1 compare favorably with established first-line regimens of chemotherapy plus anti-PD-1 agents. Across pivotal phase 3 trials with nivolumab, pembrolizumab and tislelizumab, ORRs were 47–60%, median PFS was less than 8…”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This phase 2 open-label single-arm trial is well-conducted and clearly reported, with strong scientific premise, adequate ethics, resource identification, and data availability. The main weaknesses are the lack of randomization/blinding and formal power analysis, which are inherent to the phase 2 design but limit causal inference.

Both reviewers classified the study as interventional and agreed on all dimension statuses; no divergence required reconciliation. Non-applicable criteria (e.g., randomization, blinding, cell lines, housing) were excluded from scoring. The statistics verification component checked only 1 test (a CI) and found it consistent; other statistics were not machine-verified.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
Correlation between TAP and CPS
“There was correlation between TAP score and combined positivity score (CPS) ( r = 0.83, P < 0.0001).”
Find in source
Taken as given: The correlation coefficient r=0.83 is a Pearson correlation.; The sample size n=41 is the number of patients with both TAP and CPS scores.; The p-value is two-tailed.
Method: Two-tailed p-value for Pearson correlation with n=41 using t-distribution approximation.
How we recomputed it: pR(0.83, 41)

lowinternal contradiction
The subgroup counts in Table 2 (TAP≥1% n=29, TAP≥5% n=16, TAP<1% n=11) sum to 56, exceeding the overall N=41. This is explained by overlapping subgroups (TAP≥5% is a subset of TAP≥1%), but the table does not explicitly state this overlap.
“TAP ≥1% n = 29 | TAP ≥5% n = 16 | TAP <1% n = 11”
Table 2Find in source

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

partialReviewers 1, 2
The Fc-silent design of domvanalimab may further optimize the therapeutic window by balancing efficacy with safety.
The paper provides mechanistic rationale and safety data, but no direct comparative evidence to support the claim of optimization.
Evidence: Discussion of Fc-silent design and safety profile.
“The Fc-silent design of domvanalimab may further optimize the therapeutic window by balancing efficacy with safety in the context of PD-1 blockade and chemotherapy.”
DiscussionFind in source
supportedReviewers 1, 2
Dual TIGIT and PD-1 blockade with domvanalimab and zimberelimab plus chemotherapy demonstrated encouraging efficacy.
The reported ORR of 59% and median OS of 26.7 months support the claim of encouraging efficacy, though the single-arm design limits comparison.
Evidence: ORR 59% (90% CI 44.5-71.6%), median PFS 12.9 months, median OS 26.7 months.
“Dual TIGIT and PD-1 blockade with domvanalimab and zimberelimab plus chemotherapy demonstrated encouraging efficacy”
AbstractFind in source
supportedReviewers 1, 2
The safety profile was consistent with that reported for anti-PD-1 plus platinum-based chemotherapy.
The safety data (immune-related AEs 27%, grade ≥3 TEAEs 73%) are consistent with known profiles of such combinations.
Evidence: Safety table shows TEAEs and immune-related AEs.
“the safety profile was consistent with that reported for anti-PD-1 plus platinum-based chemotherapy”
AbstractFind in source
supportedReviewers 1, 2
Clinical activity was observed across PD-L1 subgroups.
ORR and survival were reported for TAP≥1%, TAP≥5%, and TAP<1% subgroups, showing activity across all.
Evidence: ORR 62% in TAP≥1%, 69% in TAP≥5%, 46% in TAP<1%.
Tumor responses were higher in TAP ≥1% and TAP ≥5% subgroups: ORR was 62% ... and 69% ... respectively
Resultsreviewer’s wording

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

INADEQUATESurrogate endpoint
The primary efficacy endpoints are ORR, PFS, and OS. While OS is a hard clinical outcome, the primary endpoint is ORR (a surrogate), and the paper does not demonstrate target engagement at the tested dose (no PK/PD data) nor cite validated evidence linking ORR to long-term clinical benefit in this setting. The efficacy claim is based on tumor response and survival metrics without explicit validation of ORR as a surrogate for OS.
“The dual primary endpoints of safety and investigator-assessed ORR were evaluated in patients who enrolled and received any study treatment (treated analysis population).”
Find in source
INADEQUATEEffect size
The reported ORR of 59% and median OS of 26.7 months are compared favorably to historical controls, but the effect size is not anchored to a minimal clinically important difference or a predefined threshold for clinical meaningfulness. The study is descriptive without formal hypothesis testing, and the magnitude of benefit is not explicitly justified as clinically material beyond statistical confidence intervals.
“Results from the EDGE-Gastric study arm A1 compare favorably with established first-line regimens of chemotherapy plus anti-PD-1 agents. Across pivotal phase 3 trials with nivolumab, pembrolizumab and tislelizumab, ORRs were 47–60%, median PFS was less than 8 months and median OS was 15 months or less.”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions7 pass · 1 warn

The introduction cites multiple prior studies (CheckMate 649, KEYNOTE-590, RATIONALE-305) and discusses the limitations of current therapies (median OS ~14 months, 17% survival beyond 3 years). It provides a logical rationale linking TIGIT/PD-1 dual blockade to enhanced antitumor immunity, supported by preclinical and early-phase clinical data. The paper also addresses limitations of prior research, such as the need for strategies to extend benefit beyond current standards.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on PD-1 inhibitors, TIGIT biology, and preclinical/clinical evidence supporting the combination.

Evidence

paraphrase[Introduction, paragraph 1]

“The addition of programmed cell death protein 1 (PD-1) inhibitors to chemotherapy has reshaped first-line treatment for metastatic gastroesophageal cancer, expanding therapeutic options and improving outcomes.”

paraphrase[Introduction, paragraph 2]

“TIGIT suppresses T cell activation by outcompeting the activating receptor CD226 for the shared ligand CD155.”

paraphrase[Introduction, paragraph 1]

“However, durable benefit remains limited, with a median overall survival (OS) of approximately 14 months and only about 17% of patients living beyond 3 years.”

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior work on PD-1 inhibitors, TIGIT biology, and preclinical/clinical evidence for the combination, and clearly links this to the study rationale.

Evidence

paraphrase[Introduction, paragraph 1]

paraphrase[Introduction, paragraph 2]

“TIGIT expression correlates with PD-1, particularly in tumor-infiltrating T cells, and the two pathways have distinct, nonredundant roles in regulating antitumor immunity.”

paraphrase[Introduction, paragraph 1]

“However, durable benefit remains limited, with a median overall survival (OS) of approximately 14 months and only about 17% of patients living beyond 3 years.”

The study is open-label (no blinding) and single-arm (no randomization), which is appropriate for a phase 2 proof-of-concept but limits rigor. The sample size justification is descriptive, not powered for hypothesis testing. Inclusion/exclusion criteria are described, and the analysis population (treated) is defined. Outlier handling is not explicitly addressed, but the analysis population is pre-specified. Controls are not applicable as there is no comparator arm. Independent replication is not applicable as this is a single trial.

Sub-criteria

controlsN/A

power analysisINADEQUATE

blinding levelsINADEQUATE

outlier handlingNOT REPORTED

randomization unitN/A

inclusion exclusionADEQUATE

randomization methodN/A

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The study design is a single-arm, open-label phase 2 trial with no randomization or blinding, and the sample size is based on an estimation framework rather than formal power analysis.

Evidence

“The study is open label, so investigators were not blinded to the allocation of enrolled patients.”

MethodsFind in source

“The sample size justification was based on an estimation framework, and the study was designed for descriptive statistical analysis rather than formal statistical hypothesis testing with Type I error and power considerations.”

Statistical analysisFind in source

“Eligible patients were aged ≥18 years, had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, and had not received previous systemic treatment for locally advanced or metastatic disease.”

MethodsFind in source

WARNReviewer 2· 85% conf

The study is a single-arm, open-label phase 2 trial with a prespecified sample size but no randomization or blinding; the design is appropriate for a proof-of-concept but lacks a comparator arm.

Evidence

“The study is open label, so investigators were not blinded to the allocation of enrolled patients.”

MethodsFind in source

Statistical analysisFind in source

MethodsFind in source

The paper reports sex (24 male, 17 female), age range (30–82 years), and detailed demographics (race, country, ECOG PS, tumor characteristics). Sex is reported but not justified as single-sex (both sexes included). Age/weight/health are reported (age, ECOG PS). Species/strain and housing are not applicable. Demographics are comprehensive.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Sex, age, and demographics are reported; species/strain and housing are not applicable for a human trial.

Evidence

“This study included both male and female human participants ( n = 24 male and n = 17 female) aged 30–82 years.”

ResultsFind in source

“Median age in years (range) | 62 (30–82)”

Table 1Find in source

paraphrase[Table 1]

“ECOG PS, n (%) | 0 | 16 (39) | 1 | 25 (61)”

PASSReviewer 2· 90% conf

Sex, age, and demographics are reported; species/strain and housing are not applicable for a human trial.

Evidence

“This study included both male and female human participants ( n = 24 male and n = 17 female) aged 30–82 years.”

ResultsFind in source

“Median age in years (range) | 62 (30–82)”

Table 1Find in source

The paper states the study was conducted in conformance with the Declaration of Helsinki and other guidelines, and the protocol was approved by the local ethics committee at each site (Supplementary Table). All patients provided written informed consent. Regulatory compliance is stated. This meets the criteria for human research.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval and informed consent are adequately reported, with a named ethics committee and written consent.

Evidence

paraphrase[Methods, Ethics approval and consent]

“The study protocol was approved by the local ethics committee at each site (Supplementary Table).”

paraphrase[Methods, Ethics approval and consent]

“All patients provided written informed consent before any study procedures.”

“The study was conducted in full conformance with the Declaration of Helsinki, the Council for International Organizations of Medical Sciences International Ethical Guidelines, institutional review board regulations and all other applicable local regulations.”

EthicsFind in source

PASSReviewer 2· 90% conf

Ethics approval and informed consent are adequately reported, with a named ethics committee and written consent.

Evidence

paraphrase[Methods, Ethics approval and consent]

“The study protocol was approved by the local ethics committee at each site (Supplementary Table).”

“All patients provided written informed consent before any study procedures; patients were not compensated monetarily for participation in this trial.”

EthicsFind in source

The investigational products (domvanalimab, zimberelimab, FOLFOX components) are named with doses and regimens. The PD-L1 assay (VENTANA SP263) is identified with manufacturer. Statistical software (SAS 9.4) is identified. No antibodies, cell lines, or mycoplasma testing are applicable as this is a clinical trial.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational drugs and key assays are identified with manufacturer and details; software is identified.

Evidence

paraphrase[Methods, Study design]

“patients received intravenously administered domvanalimab 1,600 mg and zimberelimab 480 mg once every 4 weeks with FOLFOX (oxaliplatin 85 mg m − 2 , leucovorin 400 mg m − 2 , fluorouracil 400 mg m − 2 on day 1 and fluorouracil 2,400 mg m − 2 on days 1 and 2 (continuous 46–48-h infusion)) once every 2 weeks.”

“Tumor samples were stained using the VENTANA PD-L1 (SP263) companion diagnostics assay (Roche Diagnostics).”

MethodsFind in source

“Statistical analyses were performed using SAS software, version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational drugs and key assays are identified with manufacturer and dose; software is identified.

Evidence

“patients with no prior systemic treatment for locally advanced or metastatic GC/GEJC/EAC received intravenously administered domvanalimab 1,600 mg and zimberelimab 480 mg once every 4 weeks with FOLFOX”

MethodsFind in source

“Tumor samples were stained using the VENTANA PD-L1 (SP263) companion diagnostics assay (Roche Diagnostics).”

MethodsFind in source

“Statistical analyses were performed using SAS software, version 9.4.”

Statistical analysisFind in source

The paper uses Kaplan-Meier for survival, Clopper-Pearson for ORR, and reports 90% CIs. Exact p-values are not reported for efficacy endpoints (only for correlation), but the analysis is estimation-based, which is acceptable. Effect sizes (ORR, PFS, OS) are reported with CIs. Software is identified. Data presentation includes Kaplan-Meier curves and tables with per-group n. Mathematical plausibility checks: the subgroup counts (29+16+11=56) exceed the overall N=41, but this is explained by overlapping subgroups (TAP≥1% includes TAP≥5%), so not an inconsistency.

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate for a phase 2 trial, with named tests, CIs, and software; exact p-values are not reported but the analysis is estimation-based.

Evidence

“Median OS, median PFS, median DOR, PFS rate at 24 months and OS rate at 24 months were estimated using the Kaplan–Meier method.”

Statistical analysisFind in source

“the confirmed objective response rate was 59% (90% confidence interval (CI) 44.5–71.6%)”

AbstractFind in source

“Parameter | Overall N = 41 a | TAP ≥1% n = 29 | TAP ≥5% n = 16 | TAP <1% n = 11”

Table 2Find in source

PASSReviewer 2· 85% conf

Statistical methods are appropriate and adequately reported; p-values are not central, and effect sizes are reported with confidence intervals.

Evidence

“Median OS, median PFS, median DOR, PFS rate at 24 months and OS rate at 24 months were estimated using the Kaplan–Meier method.”

Statistical analysisFind in source

“the confirmed objective response rate was 59% (90% confidence interval (CI) 44.5–71.6%)”

AbstractFind in source

“TAP ≥1% n = 29 | TAP ≥5% n = 16 | TAP <1% n = 11”

Table 2Find in source

The data availability statement provides a concrete route: de-identified individual participant data may be available upon request via a transparency policy link, with conditions and timeframe. This is adequate for a clinical trial. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement is concrete, with a managed-access platform and conditions; no code is shared but none is required.

Evidence

“Summary and de-identified individual participant data as well as other trial information (protocols, statistical analysis plans and clinical study reports) may be available upon request.”

Data availabilityFind in source

“For information on the process or to submit a request, see https://trials.arcusbio.com/our-transparency-policy”

Data availabilityFind in source

PASSReviewer 2· 85% conf

Data availability statement is concrete, with a managed-access process and URL; no code is shared, but none is required for a clinical trial.

Evidence

“Requests for data from any qualified researcher who engages in rigorous, independent scientific research will be considered if the clinical trial data are not part of an ongoing or planned regulatory submission.”

Data availabilityFind in source

“For information on the process or to submit a request, see https://trials.arcusbio.com/our-transparency-policy”

Data availabilityFind in source

The trial is registered (NCT05329766). A reporting guideline is not explicitly mentioned, but the paper follows Nature Portfolio reporting standards. All outcomes are reported, including negative results (e.g., TAP<1% subgroup). Limitations are discussed (sample size, open-label, assay heterogeneity). Conclusions are proportional, noting the need for phase 3 validation. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is well-reported with trial registration, limitations, proportional conclusions, and funding/COI statements.

Evidence

“ClinicalTrials.gov identifier: NCT05329766”

AbstractFind in source

“EDGE-Gastric is a proof-of-concept, open-label phase 2 study, with limitations related to sample size, study design and assay heterogeneity.”

DiscussionFind in source

“This work was supported by Arcus Biosciences, Inc. and Gilead Sciences, Inc.”

AcknowledgementsFind in source

PASSReviewer 2· 90% conf

The paper is well-reported with trial registration, limitations, and funding/COI statements; reporting guideline is not explicitly mentioned but is common for Nature Medicine papers.

Evidence

“ClinicalTrials.gov identifier: NCT05329766”

AbstractFind in source

“EDGE-Gastric is a proof-of-concept, open-label phase 2 study, with limitations related to sample size, study design and assay heterogeneity.”

DiscussionFind in source

“This work was supported by Arcus Biosciences, Inc. and Gilead Sciences, Inc.”

AcknowledgementsFind in source

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT05329766

ClinicalTrials.gov

NCT05568095

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 30 references by DOI: 20 verified — 10 DOI unresolved.

UNRESOLVED10.1016/s0140-6736(21)01278-2
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Cited DOI does not resolve to any Crossref record.
UNRESOLVED10.1016/s1470-2045(23)00415-6
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Cited DOI does not resolve to any Crossref record.
UNRESOLVED10.1001/jama.2023.21318
Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial
Cited DOI does not resolve to any Crossref record.
UNRESOLVED10.1073/pnas.0904624106
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Cited DOI does not resolve to any Crossref record.
UNRESOLVED10.1200/jco.2022.40.16_suppl.397600
ARC-7: randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC)
Cited DOI does not resolve to any Crossref record.
UNRESOLVED10.1136/ijgc-2023-004700
Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study
Cited DOI does not resolve to any Crossref record.
UNRESOLVED10.1136/jitc-2024-sitc2024.1690
Phase 2 randomized study of domvanalimab combined with zimberelimab in front-line, PD-(L)1 high, locally advanced or metastatic non-small cell lung cancer (NSCLC): results from ARC-10 part 1
Cited DOI does not resolve to any Crossref record.
UNRESOLVED10.1007/s00262-025-03912-5
Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms
Cited DOI does not resolve to any Crossref record.
UNRESOLVED10.1186/s12943-024-02156-8
Regulatory T cells in immune checkpoint blockade antitumor therapy
Cited DOI does not resolve to any Crossref record.
UNRESOLVED10.1186/s13000-023-01333-5
Tumor area positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring
Cited DOI does not resolve to any Crossref record.

1 data/code link checked; 1 live.

datahttps://trials.arcusbio.com/our-transparency-policyLIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, other.

MINORconsistencyAbstract
“tumor area positivity ≥1% (PD-L1 positive) and tumor area positivity ≥5% (PD-L1 high)”
→ Consider defining TAP abbreviation at first use in abstract.
TAP is defined later in the main text.
MINORclarityMethods, Study design
“The study is open label, so investigators were not blinded to the allocation of enrolled patients.”
→ Consider rephrasing to 'The study was open-label; therefore, investigators and patients were not blinded to treatment allocation.'
Clarifies that patients were also unblinded.
MINORotherData availability
“https://trials.arcusbio.com/our-transparency-policy (https://nam12.safelinks.protection.outlook.com/?url=...)”
→ Use a clean, non-redirected URL.
The long safelinks URL is unwieldy.
MINORconsistencyAbstract
“NCT05329766 (https://clinicaltrials.gov/study/NCT05329766?term=Quemliclustat&rank=5)”
→ Remove the query parameters from the URL to avoid confusion.
The URL includes a search term 'Quemliclustat' which is unrelated to the trial.
MINORclarityDiscussion
“These observations are being further investigated in the ongoing, randomized, phase 3 STAR-221 trial ( NCT05568095 (https://clinicaltrials.gov/ct2/show/NCT05568095) )”
→ Ensure the URL is formatted consistently with other URLs.
Minor formatting inconsistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust for a phase 2 proof-of-concept, but readers should weigh the lack of a comparator arm and formal power analysis when interpreting effect sizes. No erratum is warranted based on the rigor review; however, the 10 references not found in registries should be verified to rule out fabrication, and minor copyedit issues (URLs, TAP abbreviation) could be corrected in a revision.

1.
HIGHreporting
Verify the 10 references flagged as 'not_found_in_registry' (e.g., KEYNOTE-590, KEYNOTE-859, ORIENT-16, ARC-7, ARC-10, and others) by checking their DOIs in Crossref/PubMed, and correct or replace any that are erroneous or fabricated.
References that cannot be located in any registry are a fabrication signal and must be resolved before the paper can be trusted.
2.
HIGHreporting
Add an explicit statement in the Methods (Statistical analysis) on how missing data and outliers were handled, even if none were excluded.
Both reviewers noted outlier_handling is not reported; transparency about data handling is expected for clinical trials.
3.
HIGHreporting
Explicitly mention adherence to a reporting guideline (e.g., CONSORT) in the Methods or Reporting Summary.
The paper does not explicitly state a reporting guideline, which is a minor gap in reporting transparency.
4.
MEDIUMreporting
Clarify the sample size justification by stating the expected precision or target width of the confidence interval for ORR.
The estimation framework is described but lacks a concrete precision target, which would strengthen the power_analysis sub-criterion.
5.
MEDIUMreporting
In the Discussion, explicitly acknowledge the lack of a comparator arm as a limitation and discuss potential confounding.
The single-arm design is a key limitation that should be explicitly discussed to help readers interpret the results.
6.
MEDIUMreporting
Report the number of patients with PD-L1 status assessed by central lab versus local lab, as one patient had no central tissue.
This would improve transparency in subgroup analyses and clarify the assay heterogeneity limitation.
7.
MEDIUMcopyedit
Define the TAP abbreviation at first use in the Abstract.
TAP is used in the abstract but only defined later in the main text, which may confuse readers.
8.
MEDIUMcopyedit
Replace the long safelinks URL in the Data availability section with the clean, non-redirected URL.
The current URL is unwieldy and may be broken or misleading.
9.
MEDIUMcopyedit
Remove the query parameters from the ClinicalTrials.gov URL in the Abstract (e.g., '?term=Quemliclustat&rank=5') to avoid confusion.
The URL includes an unrelated search term that could mislead readers.
10.
LOWcopyedit
Rephrase the open-label statement in Methods to clarify that both investigators and patients were unblinded.
The current phrasing only mentions investigators, which is ambiguous.
11.
LOWcopyedit
Ensure the STAR-221 trial URL in the Discussion is formatted consistently with other URLs.
Minor formatting inconsistency in the URL.

Full text (41,090 chars)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.

Janjigian YY, Oh DY, Pelster M, Wainberg ZA, Prusty S, Nelson S, DuPage A, Thompson A, Koralek DO, Sison EAR, Rha SY

DOI

10.1038/s41591-025-04022-w

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-20